🚨🧬💉Everything you wanted to know about TCR therapies* (*but were afraid to ask). Check out our new review in @NatRevDrugDisc 👇. A wonderful collaboration between @KlebanoffLab, @ND_BakerLab, @QuezadaLab, and @ToniRibas12. @MSKCancerCenter @parkerici https://t.co/HfBSUi7e6D

Congratulations to @DaniyanMd & team from @MSKCancerCenter on publication of the initial data from AML patients treated with IL-18 secreting CD371 CAR T cells @MSK. https://t.co/1Ai6kwl7HR 3 / 5 patients experienced MRD-negative morphologic leukemia free state.

🚨More cytokine-signaling magic from the @xrtcell and Garcia labs. Non-natural signal pairing with the common gamma chain receptor can drive unique transcriptional programs in T cells. 🤯This includes induction of phagocytic T cells by pairing with GSCFR!!

📢 Join us for the 2nd #VHIOBBVASymposium on Cell-Based Therapies in Oncology ‼️ 🎯 Designed for scientists, researchers, clinicians, patient representatives, and students. 📍 @santpaubcn 🗓️ November 13-14, 2025 ℹ️ https://t.co/r1bA02Tphy #CAIMI

📢New Article published @NatureCancer ! ✒️By Christopher Klebanoff and colleagues 'CAR-engineered lymphocyte persistence is governed by a FAS ligand–FAS autoregulatory circuit' 🔗 https://t.co/t6SczsYjaE

MSK’s @KlebanoffLab and team found that FAS ligand, which hampers CAR-T and CAR-NK therapies, is actually produced by immune cells themselves. Their findings, which were published in @NatureCancer, also show how a genetic decoy receptor, FAS-DNR, allows engineered cells to last

🔎 The @KlebanoffLab discovered that FASLG expression is limited primarily to endogenous T cells, NK cells, and CAR-T cells, while tumor and stromal cell expression is minimal. @NatureCancer | https://t.co/ZrDQ2xhgp0

👉Check out a commentary in @TheScientistLLC which features our take on these three amazing papers!

https://t.co/7jOX8om1ID https://t.co/LQq8fNhhhP https://t.co/xblZg8jg4s

🤯Three (!!!) new papers today in @ScienceMagazine on the application of generative AI for the de novo design of peptide/HLA binding molecules! Completely unique 3D structure and binding mode compared with natural TCRs and TCR mimics! Links to papers 👇

Project led by an amazing post doc, Dr. Fei Yi. Grateful to an amazing team of collaborators, including: @TeamJJTueb @GormallyMDPHD @Korbinian_NK @etxeberria_i @CalebLareau @LivingDrugsFilm @dbetel and so many others not on @X! Teamwork really makes the dream work 👊🥼💉🧬👏

🚨Today, in @NatureCancer, we show that CAR-T cells and CAR-NK cells contain the seeds of their own self-destruction. Disruption of a FAS-L/FAS circuit enhances CAR potency against liquid and solid cancers. https://t.co/afS9vRG4Ok @MSKCancerCenter @parkerici @MSK_DeptOfMed

Very sad to hear about the passing of Dr. Zelig Eshhar, a maverick scientist who invented a class of chimeric immune receptors that combine antibody specificity with T-cell effector function. Originally called “T-bodies”, Zelig’s discovery would enable the field of CAR therapies.

In the latest issue! Mis-splicing-derived neoantigens and cognate TCRs in splicing factor mutant leukemias

So excited to join my esteemed colleague @BernardAFox and an all star cast of speakers at the 40th @sitcancer Annual Meeting to discuss the therapeutic targeting of epitopes resulting from the #darkmatter of the cancer cell genome. Join us this November! #Tcellpower

🙌🎉🍾Celebrating Fei and his recently accepted paper in @NatureCancer! Grateful to all of our collaborators, co-authors, and excellent peer reviewers @NathanSinghLab, #SaarGill, and @JoshuaBrodyMD. Stay tuned for the final manuscript! @MSKCancerCenter #Tcellpower #NKcellpower

🚨The *second* randomized clinical study to demonstrate significant survival benefit of T cell therapy Vs. standard of care for a relapsed/refractory solid cancer. Here, GEJ/gastric cancer using claudin 18.2 CAR-T. #Tecllpower https://t.co/ZwaalAJDCF

Tomorrow at #ASCO2025, PICI CEO @DrKarenKnudsen takes center stage to receive ASCO’s Allen S. Lichter Visionary Leader Award. Time: Saturday, May 31, 9:45 AM–12:00 PM CDT | Room N – Hall B1, McCormick Place With more than 300 peer‑reviewed publications and executive leadership

In a new study published in @CellPressNews, researchers from MSK and @fredhutch show that it may be possible to develop an #immunotherapy-based approach for #AcuteMyeloidLeukemia and #myelodysplastic syndrome. “This is a potential breakthrough,” says Dr. Omar Abdel-Wahab. “We’re

#FollowFriday Chris Klebanoff is a talented medical oncologist and translational researcher @MSKCancerCenter, who is a leader in novel cell therapies. I also had the pleasure to work with him @theNCI surgery branch. Go give him a follow @KlebanoffLab!

Bravo Eric 🧬🙌!